title: Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?
authors.affiliation: Service de Rhumatologie, Hôpital de la Cavale Blanche, CHRU Brest Brest, France EA2216, INSERM ESPRI, ERI29, Laboratoire d'Immunothérapies et Pathologies lymphocytaires B, Université de Brest, and Labex "IGO", Brest, France.
authors.forename: Divi
authors.initials: D
authors.lastname: Cornec
authors.affiliation: Laboratoire d'Anatomie Pathologique et Cytologie, Hôpital Morvan, CHRU Brest,Brest, France.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Costa
authors.affiliation: Service de Rhumatologie, Hôpital de la Cavale Blanche, CHRU Brest Brest, France EA2216, INSERM ESPRI, ERI29, Laboratoire d'Immunothérapies et Pathologies lymphocytaires B, Université de Brest, and Labex "IGO", Brest, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Devauchelle-Pensec
authors.affiliation: Service de Médecine Interne, Hôpital Européen, Marseille, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Chiche
authors.affiliation: Service de Rhumatologie, Hôpital de la Cavale Blanche, CHRU Brest Brest, France EA2216, INSERM ESPRI, ERI29, Laboratoire d'Immunothérapies et Pathologies lymphocytaires B, Université de Brest, and Labex "IGO", Brest, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Saraux
authors.affiliation: EA2216, INSERM ESPRI, ERI29, Laboratoire d'Immunothérapies et Pathologies lymphocytaires B, Université de Brest, and Labex "IGO", Brest, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Pers
mesh_terms: D001402:B-Lymphocytes; D006801:Humans; D000069283:Rituximab; D012469:Salivary Glands; D012859:Sjogren's Syndrome
chemical_list: D000069283:Rituximab
keywords: B cells; DMARDs (biologic); Sjøgren's Syndrome